ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

H5 Flu IMP 2

Also written as “H5 Flu IMP 3”, “H5 Flu IMP 7” and “H5 Flu IMP 8”.

Its studies are mostly in Respiratory Syncytial Virus Infections, led by Sanofi.

Furthest: phase 1, since Mar 31, 20261 company-led study, 1 open or runningNext primary completion: Apr 4, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi11 open or runningphase 1since Mar 31, 2026Mar 31, 2026Apr 4, 2027phase 1 · NCT07516418

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 31, 2026First study: phase 1 study in Respiratory Syncytial Virus InfectionsFirst studyNCT07516418 · 360 enrolled · Australia

Ahead

  1. Apr 4, 2027Primary completion: phase 1 study in Respiratory Syncytial Virus InfectionsNCT07516418

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07516418Respiratory Syncytial Virus Infections · Australia1Active, not recruitingApr 4, 2027360

How it is read

Names in the registry

  • “H5 Flu IMP 2”, 1 entry
  • “H5 Flu IMP 3”, 1 entry
  • “H5 Flu IMP 7”, 1 entry
  • “H5 Flu IMP 8”, 1 entry
  • “H5 Flu IMP 9”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.